Israel - hebraico - Ministry of Health

teva medical marketing ltd. - ascorbic acid; biotin; colecalciferol; cyanocobalamin; dexpanthenol; folic acid; nicotinamide; phytomenadione; pyridoxine (vit b6) hydrochloride; riboflavine; thiamine (vit b1) hydrochloride; tocopherol (vit e) (as tocopheryl acetate); vitamin a palmitate - תוסף לתמיסה לאינפוזיה - ascorbic acid 80 mg / 4 ml; vitamin a palmitate 2300 iu / 4 ml; colecalciferol 400 iu / 4 ml; thiamine (vit b1) hydrochloride 1.2 mg / 4 ml; riboflavine 1.4 mg / 4 ml; nicotinamide 17 mg / 4 ml; pyridoxine (vit b6) hydrochloride 1 mg / 4 ml; dexpanthenol 5 mg / 4 ml; tocopherol (vit e) (as tocopheryl acetate) 7 iu / 4 ml; phytomenadione 0.2 mg / 4 ml; folic acid 140 mcg/ml; biotin 20 mcg/ml; cyanocobalamin 1 mcg/ml - multivitamins and other minerals, incl. combinations - multivitamins and other minerals, incl. combinations - for use as a multiple vitamin supplement for infants and children up to 11 years of age. it is also indicated in other situations where there are increased requirements for vitamins due to stress situations such as surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. the use of a multivitamin product obviates the need to speculate on the status of individual vitamin nutriture.

Israel - hebraico - Ministry of Health

lapidot medical import and marketing ltd - calcium gluconate - תמיסה להזרקה - calcium gluconate 0.94 g / 10 ml - calcium gluconate - calcium gluconate - treatment of acute symptomatic hypocalcaemia.

Israel - hebraico - Ministry of Health

lapidot medical import and marketing ltd - potassium chloride - תרכיז להכנת תמיסה לאינפוזיה - potassium chloride 14.9 g / 100 ml - potassium chloride - potassium chloride - treatment of potassium deficiency states when oral replacement is not feasable.

Israel - hebraico - Ministry of Health

abic marketing ltd, israel - levocarnitine - תמיסה - levocarnitine 30 % - levocarnitine - levocarnitine - systemic and myopathic carnitine deficiency.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 250 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation vhsd treated 500 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 1000 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.